Evaluation of efficacy, safety and tolerability...

In the News

Muhas don is new IHI board member

Prof. Kaaya. Ifakara Health Institute (IHI) Board of Governors (BOG) has appointed Prof. Sylvia Kaaya member of the IHI Board of Trustees (BOT) effective Wednesday January 10, 2018. The appointment …

Marcel steps down from IHI boards

Prof. Marcel Tanner has stepped down as Ifakara Health Institute (IHI) member of the Board of Trustees (BOT) and Board of Governors (BOG) effective Wednesday January 10, 2018. The Former …

Recent Projects

Understanding and enhancing approaches to quality improvement in small and medium sized private facilities in sub-Saharan Africa

This is an evaluation study that IHI is conducting in collaboration with London school of hygiene and tropical medicine. The research takes place in the context of an innovative intervention …

Vaccine Delivery Costing Study

As countries drive towards achieving high and equitable coverage of life-saving vaccines, the availability of sustainable, equitable, and predictable financing for vaccine delivery is essential. Over the last two decades, …

A Phase 3 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA‐824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug‐Sensitive Smear‐Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi‐Drug Resistant, Smear‐Positive Pulmonary Tuberculosis (STAND Trial).

The STAND trial, sponsored by the Global Alliance for TB Drug Development (TB Alliance) is a multi-center and multi-country study with over 50 study sites across Africa, Asia, Eastern Europe and Latin America. The trial is on the new three-drug regimen PaMZ for both TB and MDR-TB patients. In Tanzania the study is done in four sites: IHI (PI, Dr. Francis Mhimbira), Mbeya Medical Research Center-NIMR (PI, Dr. Issa Sabi), Kilimanjaro Clinical Research Institute (KCRI)-Moshi (Prof. Blandina Mmbaga) and NIMR-Mwanza (PI, Dr. George Praygod). The STAND trial is expected to run for 4 years. It is a Phase 3 Open‐Label Partially Randomized Trial.

Lead Scientists:

Francis Mhimbira

Frederick Haraka

Partners

National Institute of Medical Research
Kilimanjaro Clinical Research Institute
TB Alliance

Funders

No items found

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016